Gene Therapy (Basingstoke)

Journal

Publication Venue For

  • Rescue of retinal ganglion cells in optic nerve injury using cell-selective AAV mediated delivery of SIRT1.  28:256-264. 2021
  • Erratum: [γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia (Gene Therapy) (2015) 22: 348-355].  22:356. 2015
  • γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.  22:348-355. 2015
  • Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.  21:984-990. 2014
  • A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.  21:897-902. 2014
  • Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: Implications for preclinical gene therapy trials.  21:913-920. 2014
  • A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism.  20:733-741. 2013
  • Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.  18:1098-1102. 2011
  • IL-10 delivery by AAV5 vector attenuates inflammation in mice with pseudomonas pneumonia.  17:567-576. 2010
  • Therapeutic potential of genetically modified adult stem cells for osteopenia.  17:105-116. 2010
  • Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.  16:1300-1313. 2009
  • Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.  15:1156-1166. 2008
  • Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model.  15:1446-1453. 2008
  • Therapeutic potential of genetically modified mesenchymal stem cells.  15:711-715. 2008
  • Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965).  15:327. 2008
  • Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.  14:1380-1388. 2007
  • Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.  14:1045-1054. 2007
  • Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.  14:902-911. 2007
  • Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.  14:627-637. 2007
  • Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.  14:138-146. 2007
  • Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.  14:1111-1119. 2007
  • Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening.  13:781-788. 2006
  • Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.  13:389-399. 2006
  • Erratum: Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter (Gene Therapy (2004) vol. 11 (645-648) 10.1038/sj.gt.3302089).  13:374. 2006
  • An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery.  13:88-94. 2006
  • Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.  13:29-39. 2006
  • A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.  12:1696-1706. 2005
  • Rheumatoid arthritis: safe and sound..  12:1542-1543. 2005
  • Safe and sound.  12:1542-1543. 2005
  • A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia.  12:1163-1170. 2005
  • Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.  12:1198-1205. 2005
  • Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation.  12:1079-1088. 2005
  • Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors.  12:1042-1048. 2005
  • Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.  12:407-417. 2005
  • Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy.  12:187-193. 2005
  • Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.  12:87-94. 2005
  • Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus.  11:1482-1486. 2004
  • Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.  11:1215-1223. 2004
  • Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.  11:874-878. 2004
  • Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.  11:658-667. 2004
  • A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.  11:552-559. 2004
  • Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.  11:233-240. 2004
  • Identification of multiple genetic loci that regulate adenovirus gene therapy.  11:4-14. 2004
  • Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.  11:645-648. 2004
  • Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver.  10:1551-1558. 2003
  • Immune response following intraocular delivery of recombinant viral vectors.  10:977-982. 2003
  • Monkey see, monkey do.  10:194-196. 2003
  • Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.  9:256-262. 2002
  • The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.  9:75-80. 2002
  • Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.  9:256-262. 2002
  • Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model.  9:859-866. 2002
  • The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.  9:75-80. 2002
  • Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells.  8:1801-1807. 2001
  • Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity.  8:746-759. 2001
  • Recombinant adenovirus expressing adeno-associated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus.  8:704-712. 2001
  • Pharmacologically regulated gene expression in the retina following transduction with viral vectors.  8:442-446. 2001
  • Detection and measurement of in vitro gene transfer by gamma camera imaging.  8:291-299. 2001
  • Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain.  7:2094-2098. 2000
  • Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial..  7:867-874. 2000
  • Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial.  7:867-874. 2000
  • Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models.  7:1019-1026. 2000
  • Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients.  7:1783-1789. 2000
  • Radiation to control gene expression.  7:1085-1086. 2000
  • Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse.  5:1156-1164. 1998
  • Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism.  5:1650-1655. 1998
  • Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5).  5:798-808. 1998
  • Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.  5:121-130. 1998
  • An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.  4:317-322. 1997
  • Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae.  4:375-377. 1997
  • Incorporation of β-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression.  4:624-627. 1997
  • Use of a novel cross-linking method to modify adenovirus tropism.  4:1387-1392. 1997
  • E1A RNA transcripts amplify adenovirus-mediated tumor reduction.  3:1021-1025. 1996
  • Approaches to enhance cancer radiotherapy employing gene transfer methods.  3:1042-1068. 1996
  • In vivo gene transfer to the human biliary tract.  3:825-828. 1996
  • A method for the rapid detection of recombinant CFTR during gene therapy in cystic fibrosis.  3:685-694. 1996
  • Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene.  3:567-580. 1996
  • Towards the use of replicative adenoviral vectors for cancer gene therapy..  3:557-559. 1996
  • Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes.  3:287-297. 1996
  • Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium.  2:39-49. 1995
  • Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium..  2:38-49. 1995
  • Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.  1:332-337. 1994
  • Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines.  1:233-238. 1994
  • CNS tumor therapy by attenuated herpes simplex viruses..  1 Suppl 1. 1994
  • Gene transfer to sensory neurons using herpes virus vectors..  1 Suppl 1. 1994
  • International Standard Serial Number (issn)

  • 0969-7128
  • Electronic International Standard Serial Number (eissn)

  • 1476-5462